Validity of the timeline followback among treatment-seeking smokers in Germany.

Department of Psychiatry and Psychotherapy, University Hospital Tübingen, Osianderstr. 24, Tübingen D-72076, Germany.
Drug and alcohol dependence (Impact Factor: 3.28). 08/2009; 105(1-2):164-7. DOI: 10.1016/j.drugalcdep.2009.05.023
Source: PubMed

ABSTRACT Few studies have assessed the convergent validity of the timeline followback for smoking (TLFB-S) among treatment-seeking smokers, and there are no studies assessing its discriminant validity. Further, no studies to date have documented the psychometric properties of the TLFB in the German population. The aim of this study was therefore to test the convergent and discriminant validity of the TLFB-S among adult, treatment-seeking smokers in Germany. In the context of a smoking cessation trial, participants (N=268) completed sociodemographic, TLFB-S and other, self-aggregated, single-item (SA) smoking measures at pretreatment. During the 12-month posttreatment period, participants completed TLFB-S and biochemically validated SA measures of smoking intensity and abstinence at regular intervals. Discriminant validity analyses showed no significant associations for substance-use and sociodemographic variables and measurement discrepancy between TLFB-S and SA measures of pretreatment smoking intensity. Convergent validity analyses indicated that TLFB-S and SA measures of smoking intensity were in high agreement at both pretreatment and posttreatment. Finally, there was high concordance between TLFB-S and SA measures of abstinence at both 1- and 12-month posttreatment. This study replicated and extended the current literature on the TLFB and showed that, even across cultures, it can be a valid measure of various smoking-related variables.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Most smokers with mental illness do not receive tobacco cessation treatment. To determine whether integrating smoking cessation treatment into mental health care for veterans with posttraumatic stress disorder (PTSD) improves long-term smoking abstinence rates. A randomized controlled trial of 943 smokers with military-related PTSD who were recruited from outpatient PTSD clinics at 10 Veterans Affairs medical centers and followed up for 18 to 48 months between November 2004 and July 2009. Smoking cessation treatment integrated within mental health care for PTSD delivered by mental health clinicians (integrated care [IC]) vs referral to Veterans Affairs smoking cessation clinics (SCC). Patients received smoking cessation treatment within 3 months of study enrollment. Smoking outcomes included 12-month bioverified prolonged abstinence (primary outcome) and 7- and 30-day point prevalence abstinence assessed at 3-month intervals. Amount of smoking cessation medications and counseling sessions delivered were tested as mediators of outcome. Posttraumatic stress disorder and depression were repeatedly assessed using the PTSD Checklist and Patient Health Questionnaire 9, respectively, to determine if IC participation or quitting smoking worsened psychiatric status. Integrated care was better than SCC on prolonged abstinence (8.9% vs 4.5%; adjusted odds ratio, 2.26; 95% confidence interval [CI], 1.30-3.91; P = .004). Differences between IC vs SCC were largest at 6 months for 7-day point prevalence abstinence (78/472 [16.5%] vs 34/471 [7.2%], P < .001) and remained significant at 18 months (86/472 [18.2%] vs 51/471 [10.8%], P < .001). Number of counseling sessions received and days of cessation medication used explained 39.1% of the treatment effect. Between baseline and 18 months, psychiatric status did not differ between treatment conditions. Posttraumatic stress disorder symptoms for quitters and nonquitters improved. Nonquitters worsened slightly on the Patient Health Questionnaire 9 relative to quitters (differences ranged between 0.4 and 2.1, P = .03), whose scores did not change over time. Among smokers with military-related PTSD, integrating smoking cessation treatment into mental health care compared with referral to specialized cessation treatment resulted in greater prolonged abstinence. Identifier: NCT00118534.
    JAMA The Journal of the American Medical Association 12/2010; 304(22):2485-93. DOI:10.1001/jama.2010.1769 · 30.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Timeline Follow-Back (TLFB) is a widely used, calendar-based measure of self-reported use of (among other things) illicit substances. We examined agreement between TLFB and biological measures for illicit substances. PubMed, PsycINFO, Cochrane CENTRAL, and EMBASE were searched in December 2010. 16,633 papers screened to identify those that measured illicit substance use by both TLFB and biological measures. We extracted data on agreement between TLFB and biological measures, sample size, study type, inclusion criteria of participants, and length of recall of TLFB. Twenty-nine papers were included, almost exclusively in substance-use-disorder populations. Some studies reported several overall agreement rates, e.g. over time. Lowest and highest weighted average agreement rates were: for cannabis, 87.3% (95% confidence interval 86.9% to 87.7%) and 90.9% (90.5% to 91.4%); for cocaine, 79.3% (79.1% to 79.6%) and 84.1% (83.9% to 84.2%); for opiates 94.0% (93.5% to 94.5%) for both weighted averages; and for studies not distinguishing between substances, 88.5% (88.4 to 88.7%) and 91.0% (90.7% to 91.2%). Higher agreement was found in populations without psychiatric comorbidity, and lower agreement in randomized controlled trials. Publication bias or selective outcome reporting bias was not detected. TLFB validly detects use of illicit substances in populations with substance use disorders. Using TLFB may limit the need for biological samples, making information on illicit substance use easier and less costly to obtain and analyze.
    Addictive behaviors 11/2011; 37(3):225-33. DOI:10.1016/j.addbeh.2011.11.025 · 2.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We report results of a pilot study designed to test a novel smoking cessation intervention, Mindfulness Training for Smokers (MTS), in smokers age 18-29 years with regular episodes of binge drinking. Mindfulness is a cognitive skill of applying close moment-to-moment attention to experience with a mental posture of acceptance and non-reactivity. The MTS intervention consisted of six weekly classes that provided instruction on how to use mindfulness to manage known precursors of smoking relapse including smoking triggers, strong emotions, stressful situations, addictive thoughts, urges, and withdrawal symptoms. The MTS intervention was compared to Interactive Learning for Smokers (ILS), a time/intensity matched control group using daily non-directed walking instead of mindfulness meditation. Recruitment was conducted primarily at local technical colleges. Primary outcome measures included biochemically-confirmed smoking abstinence and reduction in alcohol use at the end of treatment (2-weeks post-quit attempt). The sample (N = 55) was 70.9% male, with a mean age of 21.9 years, and a mean of 11.76 alcoholic drinks consumed per week. Intent-to-treat analysis showed biochemically-confirmed 7-day point prevalence abstinence rates at 2-weeks post-quit for MTS = 20.0% and ILS = 4.0%, p = .08. Secondary analysis showed number of drinks per week in the first 2-weeks post-quit correlated with smoking relapse at 2-weeks post-quit (p < .01). This pilot study demonstrated that Mindfulness Training for Smokers shows promise for smoking cessation and alcohol use reduction in treating young adult smokers with alcohol abuse. Results suggest the need for a study with larger sample size and methods that reduce attrition.Trial registration: NCT01679236.
    BMC Complementary and Alternative Medicine 09/2013; 13(1):215. DOI:10.1186/1472-6882-13-215 · 1.88 Impact Factor